My latest Clinical Pipeline column at is just out.

This was an interesting piece for me, to see what's going with drugs targeting family molecules in a clinical setting, in this case an activin receptor 2a/IgG1 Fc domain fusion protein selectively mopping up ligands. The drug's been through trials in oncology, thalassemia & other conditions, but it looks like it had a good hit in pulmonary arterial .

nature.com/articles/d41591-022

@cyrilpedia As a non-clinician, I found this one very interesting, partly because of the discussion of disease mechanism

Sign in to participate in the conversation
Qoto Mastodon

QOTO: Question Others to Teach Ourselves
An inclusive, Academic Freedom, instance
All cultures welcome.
Hate speech and harassment strictly forbidden.